

PHARMACEUTICAL 2023

KalVista Pharmaceuticals Inc. Rank 88 of 446









RealRate

PHARMACEUTICAL 2023

KalVista Pharmaceuticals Inc. Rank 88 of 446



The relative strengths and weaknesses of KalVista Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of KalVista Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 78% points. The greatest weakness of KalVista Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 211%, being 168% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	193,647
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,576
Liabilities, Non-Current	7,211
Other Assets	8,055
Other Compr. Net Income	-2,429
Other Expenses	0
Other Liabilities	0
Other Net Income	14,274
Other Revenues	0
Property and Equipment	2,178
Research and Development	70,167
Selling, General and Administrative Expense	26,446

Output Variable	Value in 1000 USD
Assets	203,880
Liabilities	18,787
Expenses	96,613
Revenues	0
Stockholders Equity	185,093
Net Income	-82,339
Comprehensive Net Income	-83,554
Economic Capital Ratio	211%

